Safety and prescribing recommendations for verapamil in newly diagnosed pediatric type 1 diabetes (T1D): The CLVer...

Area of Science:

• Pediatric Endocrinology
• Cardiology
• Pharmacology

Background:

• Type 1 diabetes (T1D) management in children requires strategies to preserve beta-cell function.
• Verapamil, a calcium channel blocker, is being investigated for its potential role in beta-cell preservation in T1D.

Purpose of the Study:

• To assess the safety and side effects of verapamil in preserving beta-cells in pediatric patients newly diagnosed with T1D.
• To evaluate the tolerability and adverse event profile of verapamil in this population.

Main Methods:

• A randomized, placebo-controlled trial (CLVer study) involving 88 participants aged 8.5-17.9 years diagnosed with T1D within 31 days.
• Participants received either verapamil or placebo for 12 months, with weight-based dosing and incremental increases.
• Adverse events were monitored through serial measurements of pulse, blood pressure, liver enzymes, and electrocardiograms (ECGs).

Main Results:

• Adverse event rates were low and similar between the verapamil and placebo groups.
• No significant differences in liver function abnormalities were observed.
• Three participants on verapamil experienced asymptomatic ECG changes leading to dose reduction or discontinuation. One participant on placebo experienced complete AV block and hypotension after inadvertent verapamil overdose in a subsequent extension study.

Conclusions:

• Verapamil appears generally safe and well-tolerated in youth with newly diagnosed T1D when used with appropriate monitoring.
• Recommendations include ECG monitoring at screening and upon reaching full dosage to detect potential cardiac side effects.
• Continued research and careful monitoring are essential for optimizing verapamil use in T1D management.